menu
    • menu
    [{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bismuth Subcitrate Potassium","moa":"||Clp protease","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Bismuth Subcitrate Potassium

    Menu

    Bismuth Subcitrate Potassium

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Endo International

                            Ireland arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Endo International

                            Ireland arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bismuth Subcitrate Potassium,Metronidazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Endo Launches First Generic Version of Pylera® (Bismuth Subcitrate Potassium, Metronidazole, Tetracycline Hyd...

                            Details : Bismuth subcitrate potassium and antibacterial agents (metronidazole and tetracycline hydrochloride) capsules in combination are indicated for treating H.pylori infection and duodenal ulcer disease to eradicate H. pylori.

                            Product Name : Pylera-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 03, 2023

                            Lead Product(s) : Bismuth Subcitrate Potassium,Metronidazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth